Clinical Trial Update: Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis

View source ↗

Summary

This clinical trial update notes the completed Rebif Compliance Support Program study assessing needs in people with Multiple Sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis | Status: COMPLETED